Kevin Connors

Sparx Hockey, inventors of the Sparx Skate Sharpener, is the leading developer and manufacturer of skate sharpening equipment and related accessories for ice hockey, figure skating and sled hockey. The Sparx Sharpener is an affordable, high quality automated skate sharpener that is now used by thousands of customers around the world, including individuals, families, professional and amateur teams, rink operators and retailers. Major retail customers include DICK’s Sporting Goods, Canadian Tire, Scheels, and Pro Hockey Life to name a few. In addition, more than 25 National Hockey League teams are using the Sparx Sharpener and the company recently expanded its distribution to Europe and Russia. The company is focused on building a leadership position in skate sharpening by providing customers with the most advanced, accurate and easy-to-use skate sharpening equipment on the planet.

Adjacent to a lumbar discectomy, the Barricaid® device is designed to close large defects in the annulus, which often lead to disc reherniation and/or disc collapse. Barricaid is a permanent implant with two components - a titanium bone anchor and a flexible polymer barrier. The barrier is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position. The Barricaid has been studied in a definitive – level 1B evidence - randomized superiority trial with over 550 patients enrolled (clinicaltrials.gov NCT01283438). The study focuses on patient at highest risk of reherniation and reoperation, enrolling only those patients with large defects (width >5 mm). The co-primary endpoints of reherniation and an 8-point composite of safety and effectiveness are evaluated at 2 years, with a parallel cost effectiveness analysis. Treated patients were found superior on both endpoints, with significantly lower rates of symptomatic recurrences (12% vs. 25%, p<0.001), index-level reoperations (9% vs. 16%, p=0.01), and device or procedure related serious adverse events (SAEs) (7% vs. 17%, p=0.001). Through two years, a total of 29 reoperations were performed in Barricaid subjects in comparison to 61 procedures in Controls. Study results are published in The Spine Journal, May 2018. Barricaid is FDA-Approved For full risk/benefit, see: www.barricaid.com/instructions-for-use

Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. Our work is making a measurable difference in the world by saving, extending and improving the lives of people of all ages, in all walks of life For more than 30 years, our innovative medical technologies and noninvasive patient monitoring solutions have been solving ‘unsolvable’ problems. The result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making. Masimo is for‘what-ifers’, ‘never-say-never-ers’, and ‘world changers’—people who look beyond what others see. We're looking for people who can, do, and will make a difference. We think you'll like what you see.

Sparx Hockey, inventors of the Sparx Skate Sharpener, is the leading developer and manufacturer of skate sharpening equipment and related accessories for ice hockey, figure skating and sled hockey. The Sparx Sharpener is an affordable, high quality automated skate sharpener that is now used by thousands of customers around the world, including individuals, families, professional and amateur teams, rink operators and retailers. Major retail customers include DICK’s Sporting Goods, Canadian Tire, Scheels, and Pro Hockey Life to name a few. In addition, more than 25 National Hockey League teams are using the Sparx Sharpener and the company recently expanded its distribution to Europe and Russia. The company is focused on building a leadership position in skate sharpening by providing customers with the most advanced, accurate and easy-to-use skate sharpening equipment on the planet.

Solace Therapeutics is an emerging medical device company focused on the development of non-surgical office based treatments for common bladder disorders, such as stress urinary incontinence (SUI), Solace is dedicated to improving the patient’s quality of life by eliminating side effects typically associated with current drug and surgical therapies. Solace’s proprietary technology is designed to offer patients the following benefits: Office-based therapy that does not require anesthesia or surgery No lifestyle change required, before or after treatment Reversible at any time

Adjacent to a lumbar discectomy, the Barricaid® device is designed to close large defects in the annulus, which often lead to disc reherniation and/or disc collapse. Barricaid is a permanent implant with two components - a titanium bone anchor and a flexible polymer barrier. The barrier is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position. The Barricaid has been studied in a definitive – level 1B evidence - randomized superiority trial with over 550 patients enrolled (clinicaltrials.gov NCT01283438). The study focuses on patient at highest risk of reherniation and reoperation, enrolling only those patients with large defects (width >5 mm). The co-primary endpoints of reherniation and an 8-point composite of safety and effectiveness are evaluated at 2 years, with a parallel cost effectiveness analysis. Treated patients were found superior on both endpoints, with significantly lower rates of symptomatic recurrences (12% vs. 25%, p<0.001), index-level reoperations (9% vs. 16%, p=0.01), and device or procedure related serious adverse events (SAEs) (7% vs. 17%, p=0.001). Through two years, a total of 29 reoperations were performed in Barricaid subjects in comparison to 61 procedures in Controls. Study results are published in The Spine Journal, May 2018. Barricaid is FDA-Approved For full risk/benefit, see: www.barricaid.com/instructions-for-use